14 results on '"Cho, Kelly"'
Search Results
2. Endovascular Aneurysm Repair Devices as a Use Case for Postmarketing Surveillance of Medical Devices.
- Author
-
Wang, Xuan, Ayakulangara Panickan, Vidul, Cai, Tianrun, Xiong, Xin, Cho, Kelly, Cai, Tianxi, and Bourgeois, Florence T.
- Published
- 2023
- Full Text
- View/download PDF
3. Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program.
- Author
-
Vassy, Jason L., Posner, Daniel C., Ho, Yuk-Lam, Gagnon, David R., Galloway, Ashley, Tanukonda, Vidisha, Houghton, Serena C., Madduri, Ravi K., McMahon, Benjamin H., Tsao, Philip S., Damrauer, Scott M., O'Donnell, Christopher J., Assimes, Themistocles L., Casas, Juan P., Gaziano, J. Michael, Pencina, Michael J., Sun, Yan V., Cho, Kelly, and Wilson, Peter W.F.
- Published
- 2023
- Full Text
- View/download PDF
4. Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait
- Author
-
Verma, Anurag, Huffman, Jennifer E., Gao, Lina, Minnier, Jessica, Wu, Wen-Chih, Cho, Kelly, Ho, Yuk-Lam, Gorman, Bryan R., Pyarajan, Saiju, Rajeevan, Nallakkandi, Garcon, Helene, Joseph, Jacob, McGeary, John E., Suzuki, Ayako, Reaven, Peter D., Wan, Emily S., Lynch, Julie A., Petersen, Jeffrey M., Meigs, James B., Freiberg, Matthew S., Gatsby, Elise, Lynch, Kristine E., Zekavat, Seyedeh Maryam, Natarajan, Pradeep, Dalal, Sharvari, Jhala, Darshana N., Arjomandi, Mehrdad, Bonomo, Robert A., Thompson, Trevor K., Pathak, Gita A., Zhou, Jin J., Donskey, Curtis J., Madduri, Ravi K., Wells, Quinn S., Gelernter, Joel, Huang, Rose D. L., Polimanti, Renato, Chang, Kyong-Mi, Liao, Katherine P., Tsao, Philip S., Sun, Yan V., Wilson, Peter W. F., O’Donnell, Christopher J., Hung, Adriana M., Gaziano, J. Michael, Hauger, Richard L., Iyengar, Sudha K., and Luoh, Shiuh-Wen
- Subjects
Black or African American ,Hemoglobins ,Internal Medicine ,COVID-19 ,Humans ,Acute Kidney Injury ,Kidney ,Original Investigation ,Sickle Cell Trait - Abstract
IMPORTANCE: Sickle cell trait (SCT), defined as the presence of 1 hemoglobin beta sickle allele (rs334-T) and 1 normal beta allele, is prevalent in millions of people in the US, particularly in individuals of African and Hispanic ancestry. However, the association of SCT with COVID-19 is unclear. OBJECTIVE: To assess the association of SCT with the prepandemic health conditions in participants of the Million Veteran Program (MVP) and to assess the severity and sequelae of COVID-19. DESIGN, SETTING, AND PARTICIPANTS: COVID-19 clinical data include 2729 persons with SCT, of whom 353 had COVID-19, and 129 848 SCT-negative individuals, of whom 13 488 had COVID-19. Associations between SCT and COVID-19 outcomes were examined using firth regression. Analyses were performed by ancestry and adjusted for sex, age, age squared, and ancestral principal components to account for population stratification. Data for the study were collected between March 2020 and February 2021. EXPOSURES: The hemoglobin beta S (HbS) allele (rs334-T). MAIN OUTCOMES AND MEASURES: This study evaluated 4 COVID-19 outcomes derived from the World Health Organization severity scale and phenotypes derived from International Classification of Diseases codes in the electronic health records. RESULTS: Of the 132 577 MVP participants with COVID-19 data, mean (SD) age at the index date was 64.8 (13.1) years. Sickle cell trait was present in 7.8% of individuals of African ancestry and associated with a history of chronic kidney disease, diabetic kidney disease, hypertensive kidney disease, pulmonary embolism, and cerebrovascular disease. Among the 4 clinical outcomes of COVID-19, SCT was associated with an increased COVID-19 mortality in individuals of African ancestry (n = 3749; odds ratio, 1.77; 95% CI, 1.13 to 2.77; P = .01). In the 60 days following COVID-19, SCT was associated with an increased incidence of acute kidney failure. A counterfactual mediation framework estimated that on average, 20.7% (95% CI, −3.8% to 56.0%) of the total effect of SCT on COVID-19 fatalities was due to acute kidney failure. CONCLUSIONS AND RELEVANCE: In this genetic association study, SCT was associated with preexisting kidney comorbidities, increased COVID-19 mortality, and kidney morbidity.
- Published
- 2022
5. Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans.
- Author
-
Dickerman, Barbra A., Madenci, Arin L., Gerlovin, Hanna, Kurgansky, Katherine E., Wise, Jessica K., Figueroa Muñiz, Michael J., Ferolito, Brian R., Gagnon, David R., Gaziano, J. Michael, Cho, Kelly, Casas, Juan P., and Hernán, Miguel A.
- Published
- 2022
- Full Text
- View/download PDF
6. Long-Term Body Mass Index Variability and Adverse Cardiovascular Outcomes.
- Author
-
Almuwaqqat, Zakaria, Hui, Qin, Liu, Chang, Zhou, Jin J., Voight, Benjamin F., Ho, Yuk-Lam, Posner, Daniel C., Vassy, Jason L., Gaziano, J. Michael, Cho, Kelly, Wilson, Peter W. F., and Sun, Yan V.
- Published
- 2024
- Full Text
- View/download PDF
7. Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older.
- Author
-
Orkaby, Ariela R., Driver, Jane A., Ho, Yuk-Lam, Lu, Bing, Costa, Lauren, Honerlaw, Jacqueline, Galloway, Ashley, Vassy, Jason L., Forman, Daniel E., Gaziano, J. Michael, Gagnon, David R., Wilson, Peter W. F., Cho, Kelly, and Djousse, Luc
- Subjects
STATINS (Cardiovascular agents) ,CARDIOVASCULAR disease related mortality ,CARDIOVASCULAR diseases risk factors ,DISEASES in older people ,THERAPEUTICS research ,CARDIOVASCULAR disease prevention ,ATHEROSCLEROSIS prevention ,CAUSES of death ,RESEARCH ,ANTILIPEMIC agents ,MORTALITY ,RESEARCH methodology ,RETROSPECTIVE studies ,EVALUATION research ,MEDICAL cooperation ,COMPARATIVE studies ,VETERANS ,PROBABILITY theory - Abstract
Importance: Data are limited regarding statin therapy for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults 75 years and older.Objective: To evaluate the role of statin use for mortality and primary prevention of ASCVD in veterans 75 years and older.Design, Setting, and Participants: Retrospective cohort study that used Veterans Health Administration (VHA) data on adults 75 years and older, free of ASCVD, and with a clinical visit in 2002-2012. Follow-up continued through December 31, 2016. All data were linked to Medicare and Medicaid claims and pharmaceutical data. A new-user design was used, excluding those with any prior statin use. Cox proportional hazards models were fit to evaluate the association of statin use with outcomes. Analyses were conducted using propensity score overlap weighting to balance baseline characteristics.Exposures: Any new statin prescription.Main Outcomes and Measures: The primary outcomes were all-cause and cardiovascular mortality. Secondary outcomes included a composite of ASCVD events (myocardial infarction, ischemic stroke, and revascularization with coronary artery bypass graft surgery or percutaneous coronary intervention).Results: Of 326 981 eligible veterans (mean [SD] age, 81.1 [4.1] years; 97% men; 91% white), 57 178 (17.5%) newly initiated statins during the study period. During a mean follow-up of 6.8 (SD, 3.9) years, a total 206 902 deaths occurred including 53 296 cardiovascular deaths, with 78.7 and 98.2 total deaths/1000 person-years among statin users and nonusers, respectively (weighted incidence rate difference [IRD]/1000 person-years, -19.5 [95% CI, -20.4 to -18.5]). There were 22.6 and 25.7 cardiovascular deaths per 1000 person-years among statin users and nonusers, respectively (weighted IRD/1000 person-years, -3.1 [95 CI, -3.6 to -2.6]). For the composite ASCVD outcome there were 123 379 events, with 66.3 and 70.4 events/1000 person-years among statin users and nonusers, respectively (weighted IRD/1000 person-years, -4.1 [95% CI, -5.1 to -3.0]). After propensity score overlap weighting was applied, the hazard ratio was 0.75 (95% CI, 0.74-0.76) for all-cause mortality, 0.80 (95% CI, 0.78-0.81) for cardiovascular mortality, and 0.92 (95% CI, 0.91-0.94) for a composite of ASCVD events when comparing statin users with nonusers.Conclusions and Relevance: Among US veterans 75 years and older and free of ASCVD at baseline, new statin use was significantly associated with a lower risk of all-cause and cardiovascular mortality. Further research, including from randomized clinical trials, is needed to more definitively determine the role of statin therapy in older adults for primary prevention of ASCVD. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
8. Rates of ICD-10 Code U09.9 Documentation and Clinical Characteristics of VA Patients With Post–COVID-19 Condition.
- Author
-
Wander, Pandora L., Baraff, Aaron, Fox, Alexandra, Cho, Kelly, Maripuri, Monika, Honerlaw, Jacqueline P., Ho, Yuk-Lam, Dey, Andrew T., O'Hare, Ann M., Bohnert, Amy S. B., Boyko, Edward J., Maciejewski, Matthew L., Viglianti, Elizabeth, Iwashyna, Theodore J., Hynes, Denise M., Osborne, Thomas F., and Ioannou, George N.
- Published
- 2023
- Full Text
- View/download PDF
9. Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy: A Phenome-Wide Association Study.
- Author
-
Cai, Tianxi, Zhang, Yichi, Ho, Yuk-Lam, Link, Nicholas, Sun, Jiehuan, Huang, Jie, Cai, Tianrun A., Damrauer, Scott, Ahuja, Yuri, Honerlaw, Jacqueline, Costa, Lauren, Schubert, Petra, Hong, Chuan, Gagnon, David, Sun, Yan V., Gaziano, J. Michael, Wilson, Peter, Cho, Kelly, Tsao, Philip, and O'Donnell, Christopher J.
- Published
- 2018
- Full Text
- View/download PDF
10. Prescription Opioid Duration of Action and the Risk of Unintentional Overdose Among Patients Receiving Opioid Therapy.
- Author
-
Miller, Matthew, Barber, Catherine W., Leatherman, Sarah, Fonda, Jennifer, Hermos, John A., Cho, Kelly, and Gagnon, David R.
- Published
- 2015
- Full Text
- View/download PDF
11. Estimation of Atherosclerotic Cardiovascular Disease Risk Among Patients in the Veterans Affairs Health Care System.
- Author
-
Vassy, Jason L., Lu, Bing, Ho, Yuk-Lam, Galloway, Ashley, Raghavan, Sridharan, Honerlaw, Jacqueline, Tarko, Laura, Russo, John, Qazi, Saadia, Orkaby, Ariela R., Tanukonda, Vidisha, Djousse, Luc, Gaziano, J. Michael, Gagnon, David R., Cho, Kelly, and Wilson, Peter W. F.
- Published
- 2020
- Full Text
- View/download PDF
12. GLP1R Gene Expression and Kidney Disease Progression.
- Author
-
Triozzi JL, Yu Z, Giri A, Chen HC, Wilson OD, Ferolito B, Ikizler TA, Akwo EA, Robinson-Cohen C, Gaziano JM, Cho K, Phillips LS, Tao R, Pereira AC, and Hung AM
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Retrospective Studies, Gene Expression, United States epidemiology, Kidney Failure, Chronic genetics, Glomerular Filtration Rate, Glucagon-Like Peptide-1 Receptor genetics, Disease Progression
- Abstract
Importance: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have nephroprotective properties beyond those related to weight loss and glycemic control., Objective: To investigate the association of genetically proxied GLP-1RAs with kidney disease progression., Design, Setting, and Participants: This genetic association study assembled a national retrospective cohort of veterans aged 18 years or older from the US Department of Veterans Affairs Million Veteran Program between January 10, 2011, and December 31, 2021. Data were analyzed from November 2023 to February 2024., Exposures: Genetic risk score for systemic GLP1R gene expression that was calculated for each study participant based on genetic variants associated with GLP1R mRNA levels across all tissue samples within the Genotype-Tissue Expression project., Main Outcomes and Measures: The primary composite outcome was incident end-stage kidney disease or a 40% decline in estimated glomerular filtration rate. Cox proportional hazards regression survival analysis assessed the association between genetically proxied GLP-1RAs and kidney disease progression., Results: Among 353 153 individuals (92.5% men), median age was 66 years (IQR, 58.0-72.0 years) and median follow-up was 5.1 years (IQR, 3.1-7.2 years). Overall, 25.7% had diabetes, and 45.0% had obesity. A total of 4.6% experienced kidney disease progression. Overall, higher genetic GLP1R gene expression was associated with a lower risk of kidney disease progression in the unadjusted model (hazard ratio [HR], 0.96; 95% CI, 0.92-0.99; P = .02) and in the fully adjusted model accounting for baseline patient characteristics, body mass index, and the presence or absence of diabetes (HR, 0.96; 95% CI, 0.92-1.00; P = .04). The results were similar in sensitivity analyses stratified by diabetes or obesity status., Conclusions and Relevance: In this genetic association study, higher GLP1R gene expression was associated with a small reduction in risk of kidney disease progression. These findings support pleiotropic nephroprotective mechanisms of GLP-1RAs independent of their effects on body weight and glycemic control.
- Published
- 2024
- Full Text
- View/download PDF
13. Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait.
- Author
-
Verma A, Huffman JE, Gao L, Minnier J, Wu WC, Cho K, Ho YL, Gorman BR, Pyarajan S, Rajeevan N, Garcon H, Joseph J, McGeary JE, Suzuki A, Reaven PD, Wan ES, Lynch JA, Petersen JM, Meigs JB, Freiberg MS, Gatsby E, Lynch KE, Zekavat SM, Natarajan P, Dalal S, Jhala DN, Arjomandi M, Bonomo RA, Thompson TK, Pathak GA, Zhou JJ, Donskey CJ, Madduri RK, Wells QS, Gelernter J, Huang RDL, Polimanti R, Chang KM, Liao KP, Tsao PS, Sun YV, Wilson PWF, O'Donnell CJ, Hung AM, Gaziano JM, Hauger RL, Iyengar SK, and Luoh SW
- Subjects
- Black or African American genetics, Hemoglobins, Humans, Kidney, Acute Kidney Injury complications, Acute Kidney Injury epidemiology, COVID-19 epidemiology, Sickle Cell Trait complications, Sickle Cell Trait epidemiology, Sickle Cell Trait genetics
- Abstract
Importance: Sickle cell trait (SCT), defined as the presence of 1 hemoglobin beta sickle allele (rs334-T) and 1 normal beta allele, is prevalent in millions of people in the US, particularly in individuals of African and Hispanic ancestry. However, the association of SCT with COVID-19 is unclear., Objective: To assess the association of SCT with the prepandemic health conditions in participants of the Million Veteran Program (MVP) and to assess the severity and sequelae of COVID-19., Design, Setting, and Participants: COVID-19 clinical data include 2729 persons with SCT, of whom 353 had COVID-19, and 129 848 SCT-negative individuals, of whom 13 488 had COVID-19. Associations between SCT and COVID-19 outcomes were examined using firth regression. Analyses were performed by ancestry and adjusted for sex, age, age squared, and ancestral principal components to account for population stratification. Data for the study were collected between March 2020 and February 2021., Exposures: The hemoglobin beta S (HbS) allele (rs334-T)., Main Outcomes and Measures: This study evaluated 4 COVID-19 outcomes derived from the World Health Organization severity scale and phenotypes derived from International Classification of Diseases codes in the electronic health records., Results: Of the 132 577 MVP participants with COVID-19 data, mean (SD) age at the index date was 64.8 (13.1) years. Sickle cell trait was present in 7.8% of individuals of African ancestry and associated with a history of chronic kidney disease, diabetic kidney disease, hypertensive kidney disease, pulmonary embolism, and cerebrovascular disease. Among the 4 clinical outcomes of COVID-19, SCT was associated with an increased COVID-19 mortality in individuals of African ancestry (n = 3749; odds ratio, 1.77; 95% CI, 1.13 to 2.77; P = .01). In the 60 days following COVID-19, SCT was associated with an increased incidence of acute kidney failure. A counterfactual mediation framework estimated that on average, 20.7% (95% CI, -3.8% to 56.0%) of the total effect of SCT on COVID-19 fatalities was due to acute kidney failure., Conclusions and Relevance: In this genetic association study, SCT was associated with preexisting kidney comorbidities, increased COVID-19 mortality, and kidney morbidity.
- Published
- 2022
- Full Text
- View/download PDF
14. APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program.
- Author
-
Hung AM, Shah SC, Bick AG, Yu Z, Chen HC, Hunt CM, Wendt F, Wilson O, Greevy RA, Chung CP, Suzuki A, Ho YL, Akwo E, Polimanti R, Zhou J, Reaven P, Tsao PS, Gaziano JM, Huffman JE, Joseph J, Luoh SW, Iyengar S, Chang KM, Casas JP, Matheny ME, O'Donnell CJ, Cho K, Tao R, Susztak K, Robinson-Cohen C, Tuteja S, and Siew ED
- Subjects
- Black or African American genetics, Aged, Apolipoprotein L1 genetics, Cohort Studies, Female, Hospitalization, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Acute Kidney Injury genetics, COVID-19, Veterans
- Abstract
Importance: Coronavirus disease 2019 (COVID-19) confers significant risk of acute kidney injury (AKI). Patients with COVID-19 with AKI have high mortality rates., Objective: Individuals with African ancestry with 2 copies of apolipoprotein L1 (APOL1) variants G1 or G2 (high-risk group) have significantly increased rates of kidney disease. We tested the hypothesis that the APOL1 high-risk group is associated with a higher-risk of COVID-19-associated AKI and death., Design, Setting, and Participants: This retrospective cohort study included 990 participants with African ancestry enrolled in the Million Veteran Program who were hospitalized with COVID-19 between March 2020 and January 2021 with available genetic information., Exposures: The primary exposure was having 2 APOL1 risk variants (RV) (APOL1 high-risk group), compared with having 1 or 0 risk variants (APOL1 low-risk group)., Main Outcomes and Measures: The primary outcome was AKI. The secondary outcomes were stages of AKI severity and death. Multivariable logistic regression analyses adjusted for preexisting comorbidities, medications, and inpatient AKI risk factors; 10 principal components of ancestry were performed to study these associations. We performed a subgroup analysis in individuals with normal kidney function prior to hospitalization (estimated glomerular filtration rate ≥60 mL/min/1.73 m2)., Results: Of the 990 participants with African ancestry, 905 (91.4%) were male with a median (IQR) age of 68 (60-73) years. Overall, 392 (39.6%) patients developed AKI, 141 (14%) developed stages 2 or 3 AKI, 28 (3%) required dialysis, and 122 (12.3%) died. One hundred twenty-five (12.6%) of the participants were in the APOL1 high-risk group. Patients categorized as APOL1 high-risk group had significantly higher odds of AKI (adjusted odds ratio [OR], 1.95; 95% CI, 1.27-3.02; P = .002), higher AKI severity stages (OR, 2.03; 95% CI, 1.37-2.99; P < .001), and death (OR, 2.15; 95% CI, 1.22-3.72; P = .007). The association with AKI persisted in the subgroup with normal kidney function (OR, 1.93; 95% CI, 1.15-3.26; P = .01). Data analysis was conducted between February 2021 and April 2021., Conclusions and Relevance: In this cohort study of veterans with African ancestry hospitalized with COVID-19 infection, APOL1 kidney risk variants were associated with higher odds of AKI, AKI severity, and death, even among individuals with prior normal kidney function.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.